Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1 Abstract #503

Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Aim(s): We report long-term SD in a glucagonoma pt enrolled in RADIANT-1.
Materials and methods: A man aged 46 was diagnosed with glucagonoma in 1990 with tumors in the pancreas (4 cm) and liver (5 cm): p-glucagon >1000 ng/L (ref, <140 ng/L), pancreatic polypeptide (PP)=170 pmol/L (ref, <100 pmol/L), Chromogranin A (CgA)=609 µg/L (ref, <350 µg/L). Pancreas, spleen, and liver metastases (met) were resected, and interferon-a 5×/wk was initiated. Recurrent disease was confirmed in Sept 1996 (CgA-/PP-/glucagon-positive liver tumor). Subsequent met were treated with surgery, radiofrequency ablation (RFA), and chemotherapy (streptozotocin+5-FU). In Feb 2007, multiple liver met not suitable for resection or RFA were identified; after 7 y, chemotherapy was stopped and the pt was enrolled in RADIANT-1 and received Everolimus alone.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby

To read results and conclusion, please login ...

Further abstracts you may be interested in

#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy
Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Alexandre Teulé Vega
#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET
Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
#871 Success with Lutetium-177 DOTATATE Therapy in Cushing’s Syndrome Caused by Functional Pancreatic Neuroendocrine Tumor (pNET) with Ectopic Adrenocorticotropic Hormone (ACTH) Secretion Refractory to Concomitant Everolimus, Pasireotide and Metyrapone
Introduction: We report a case of a 59-year-old female presenting with florid ACTH-dependent Cushing’s syndrome complicated by pulmonary cryptococcal infection.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Bryan A Chan
Authors: Chan B A, Wyld D, Burge M, Cuneo R, ...
#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting
Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Michela Del Prete
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.